Understanding the intricate interplay between HDAC2 and PJA2 offers a promising avenue for the development of targeted therapies aimed at restoring balance and enhancing the efficacy of current treatments, particularly in the context of CRC. Here, HDAC2 is linked to colorectal carcinoma.